Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Gaucher disease: Initial assessment, monitoring, and clinical course

Derralynn Hughes, MD
Section Editor
Sihoun Hahn, MD, PhD
Deputy Editor
Elizabeth TePas, MD, MS


Gaucher disease (GD) is an inborn error of metabolism that affects the recycling of cellular glycolipids. GD is one of the most common lysosomal storage diseases. Glucocerebroside (also called glucosylceramide) and several related compounds that ordinarily are degraded to glucose and lipid components accumulate within the lysosomes of cells.

GD is categorized into three clinical types. The disease involves the visceral organs, bone marrow, and bone in almost all affected patients. Type 1 (GD1, MIM #230800) is the most common. It is distinguished from type 2 (GD2, MIM #230900) and type 3 (GD3, MIM #231000) by the lack of characteristic involvement of the central nervous system (CNS).

Additional resources for information about GD for patients and families are listed in the table (table 1). Guidelines for the evaluation and monitoring of children and adults with GD, based upon data from the International Collaborative Gaucher Group (ICGG) Registry and published data from international consensus panels, are incorporated into the discussion in this topic [1-7].

The initial assessment and routine monitoring of patients with GD will be discussed here. The pathogenesis, genetics, clinical manifestations, diagnosis, and treatment are discussed separately. (See "Gaucher disease: Pathogenesis, clinical manifestations, and diagnosis" and "Gaucher disease: Treatment".)


Each patient should undergo a comprehensive initial assessment of all potentially affected organ systems since there is significant variability in the manifestations, severity, and progression of GD that will impact treatment options (table 2) [8]. A decision is made regarding whether Gaucher-specific therapy is indicated after the extent of symptoms and rate of progression are established. Treatment is then individualized to achieve specific therapeutic goals (table 3) [9]. (See "Gaucher disease: Treatment".)

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Mar 21, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Charrow J, Andersson HC, Kaplan P, et al. Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations. J Pediatr 2004; 144:112.
  2. Grabowski GA, Andria G, Baldellou A, et al. Pediatric non-neuronopathic Gaucher disease: presentation, diagnosis and assessment. Consensus statements. Eur J Pediatr 2004; 163:58.
  3. Baldellou A, Andria G, Campbell PE, et al. Paediatric non-neuronopathic Gaucher disease: recommendations for treatment and monitoring. Eur J Pediatr 2004; 163:67.
  4. Vellodi A, Bembi B, de Villemeur TB, et al. Management of neuronopathic Gaucher disease: a European consensus. J Inherit Metab Dis 2001; 24:319.
  5. Weinreb NJ, Aggio MC, Andersson HC, et al. Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients. Semin Hematol 2004; 41:15.
  6. Hughes D, Cappellini MD, Berger M, et al. Recommendations for the management of the haematological and onco-haematological aspects of Gaucher disease. Br J Haematol 2007; 138:676.
  7. Andersson HC, Charrow J, Kaplan P, et al. Individualization of long-term enzyme replacement therapy for Gaucher disease. Genet Med 2005; 7:105.
  8. Pastores GM, Weinreb NJ, Aerts H, et al. Therapeutic goals in the treatment of Gaucher disease. Semin Hematol 2004; 41:4.
  9. Jmoudiak M, Futerman AH. Gaucher disease: pathological mechanisms and modern management. Br J Haematol 2005; 129:178.
  10. Tayebi N, Walker J, Stubblefield B, et al. Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism? Mol Genet Metab 2003; 79:104.
  11. Bamiou DE, Campbell P, Liasis A, et al. Audiometric abnormalities in children with Gaucher disease type 3. Neuropediatrics 2001; 32:136.
  12. Tantawy AA, Sherif EM, Adly AA, et al. Evoked potentials and neurocognitive functions in pediatric Egyptian Gaucher patients on enzyme replacement therapy: a single center experience. J Inherit Metab Dis 2013; 36:1025.
  13. Mistry PK, Sirrs S, Chan A, et al. Pulmonary hypertension in type 1 Gaucher's disease: genetic and epigenetic determinants of phenotype and response to therapy. Mol Genet Metab 2002; 77:91.
  14. Giraldo P, Cenarro A, Alfonso P, et al. Chitotriosidase genotype and plasma activity in patients type 1 Gaucher's disease and their relatives (carriers and non carriers). Haematologica 2001; 86:977.
  15. Hollak CE, Maas M, Aerts JM. Clinically relevant therapeutic endpoints in type I Gaucher disease. J Inherit Metab Dis 2001; 24 Suppl 2:97.
  16. Lacerda L, Arosa FA, Lacerda R, et al. T cell numbers relate to bone involvement in Gaucher disease. Blood Cells Mol Dis 1999; 25:130.
  17. Stein P, Yang R, Liu J, et al. Evaluation of high density lipoprotein as a circulating biomarker of Gaucher disease activity. J Inherit Metab Dis 2011; 34:429.
  18. Czartoryska B, Tylki-Szymańska A, Lugowska A. Changes in serum chitotriosidase activity with cessation of replacement enzyme (cerebrosidase) administration in Gaucher disease. Clin Biochem 2000; 33:147.
  19. Hollak CE, van Weely S, van Oers MH, Aerts JM. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest 1994; 93:1288.
  20. Cox TM, Aerts JM, Belmatoug N, et al. Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring. J Inherit Metab Dis 2008; 31:319.
  21. Moran MT, Schofield JP, Hayman AR, et al. Pathologic gene expression in Gaucher disease: up-regulation of cysteine proteinases including osteoclastic cathepsin K. Blood 2000; 96:1969.
  22. Boot RG, Verhoek M, de Fost M, et al. Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. Blood 2004; 103:33.
  23. Deegan PB, Moran MT, McFarlane I, et al. Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher disease. Blood Cells Mol Dis 2005; 35:259.
  24. Deegan PB, Pavlova E, Tindall J, et al. Osseous manifestations of adult Gaucher disease in the era of enzyme replacement therapy. Medicine (Baltimore) 2011; 90:52.
  25. Rolfs A, Giese AK, Grittner U, et al. Glucosylsphingosine is a highly sensitive and specific biomarker for primary diagnostic and follow-up monitoring in Gaucher disease in a non-Jewish, Caucasian cohort of Gaucher disease patients. PLoS One 2013; 8:e79732.
  26. Vellodi A, Foo Y, Cole TJ. Evaluation of three biochemical markers in the monitoring of Gaucher disease. J Inherit Metab Dis 2005; 28:585.
  27. Stein P, Malhotra A, Haims A, et al. Focal splenic lesions in type I Gaucher disease are associated with poor platelet and splenic response to macrophage-targeted enzyme replacement therapy. J Inherit Metab Dis 2010; 33:769.
  28. Patlas M, Hadas-Halpern I, Abrahamov A, et al. Spectrum of abdominal sonographic findings in 103 pediatric patients with Gaucher disease. Eur Radiol 2002; 12:397.
  29. Grabowski GA. Recent clinical progress in Gaucher disease. Curr Opin Pediatr 2005; 17:519.
  30. Maas M, van Kuijk C, Stoker J, et al. Quantification of bone involvement in Gaucher disease: MR imaging bone marrow burden score as an alternative to Dixon quantitative chemical shift MR imaging--initial experience. Radiology 2003; 229:554.
  31. Allison JW, James CA, Arnold GL, et al. Reconversion of bone marrow in Gaucher disease treated with enzyme therapy documented by MR. Pediatr Radiol 1998; 28:237.
  32. Poll LW, Willers R, Häussinger D, et al. [MRI bone marrow findings in 63 patients with type I Gaucher disease]. Rofo 2010; 182:979.
  33. Greulich WW, Pyle SI. Radiographic atlas of skeletal development of the hand and wrist, Stanford University Press, Stanford 1976.
  34. Bembi B, Ciana G, Mengel E, et al. Bone complications in children with Gaucher disease. Br J Radiol 2002; 75 Suppl 1:A37.
  35. Maas M, Poll LW, Terk MR. Imaging and quantifying skeletal involvement in Gaucher disease. Br J Radiol 2002; 75 Suppl 1:A13.
  36. Poll LW, Maas M, Terk MR, et al. Response of Gaucher bone disease to enzyme replacement therapy. Br J Radiol 2002; 75 Suppl 1:A25.
  37. Crabtree NJ, Kibirige MS, Fordham JN, et al. The relationship between lean body mass and bone mineral content in paediatric health and disease. Bone 2004; 35:965.
  38. Hoffman GM, Nowakowski R, Troshynski TJ, et al. Risk reduction in pediatric procedural sedation by application of an American Academy of Pediatrics/American Society of Anesthesiologists process model. Pediatrics 2002; 109:236.
  39. Whitfield PD, Nelson P, Sharp PC, et al. Correlation among genotype, phenotype, and biochemical markers in Gaucher disease: implications for the prediction of disease severity. Mol Genet Metab 2002; 75:46.
  40. Hicks CL, von Baeyer CL, Spafford PA, et al. The Faces Pain Scale-Revised: toward a common metric in pediatric pain measurement. Pain 2001; 93:173.
  41. Charrow J, Esplin JA, Gribble TJ, et al. Gaucher disease: recommendations on diagnosis, evaluation, and monitoring. Arch Intern Med 1998; 158:1754.
  42. Harris CM, Taylor DS, Vellodi A. Ocular motor abnormalities in Gaucher disease. Neuropediatrics 1999; 30:289.
  43. Davies EH, Mengel E, Tylki-Szymanska A, et al. Four-year follow-up of chronic neuronopathic Gaucher disease in Europeans using a modified severity scoring tool. J Inherit Metab Dis 2011; 34:1053.
  44. Weinreb NJ, Cappellini MD, Cox TM, et al. A validated disease severity scoring system for adults with type 1 Gaucher disease. Genet Med 2010; 12:44.
  45. Di Rocco M, Giona F, Carubbi F, et al. A new severity score index for phenotypic classification and evaluation of responses to treatment in type I Gaucher disease. Haematologica 2008; 93:1211.
  46. Gielchinsky Y, Elstein D, Green R, et al. High prevalence of low serum vitamin B12 in a multi-ethnic Israeli population. Br J Haematol 2001; 115:707.
  47. Billett HH, Rizvi S, Sawitsky A. Coagulation abnormalities in patients with Gaucher's disease: effect of therapy. Am J Hematol 1996; 51:234.
  48. Seligsohn U, Zitman D, Many A, Klibansky C. Coexistence of factor XI (plasma thromboplastin antecedent) deficiency and Gaucher's disease. Isr J Med Sci 1976; 12:1448.
  49. Lachmann RH, Wight DG, Lomas DJ, et al. Massive hepatic fibrosis in Gaucher's disease: clinico-pathological and radiological features. QJM 2000; 93:237.
  50. Bohte AE, van Dussen L, Akkerman EM, et al. Liver fibrosis in type I Gaucher disease: magnetic resonance imaging, transient elastography and parameters of iron storage. PLoS One 2013; 8:e57507.
  51. Rosenbloom BE, Weinreb NJ, Zimran A, et al. Gaucher disease and cancer incidence: a study from the Gaucher Registry. Blood 2005; 105:4569.
  52. Mariani G, Erba PA. Radionuclide evaluation of Gaucher disease. In: Gaucher disease, Futerman AH, Zimran A (Eds), CRC Press, Boca Raton 2006. p.287.
  53. Erba PA, Minichilli F, Giona F, et al. 99mTc-sestamibi scintigraphy to monitor the long-term efficacy of enzyme replacement therapy on bone marrow infiltration in patients with Gaucher disease. J Nucl Med 2013; 54:1717.
  54. Maas M, Hollak CE, Akkerman EM, et al. Quantification of skeletal involvement in adults with type I Gaucher's disease: fat fraction measured by Dixon quantitative chemical shift imaging as a valid parameter. AJR Am J Roentgenol 2002; 179:961.
  55. Kauli R, Zaizov R, Lazar L, et al. Delayed growth and puberty in patients with Gaucher disease type 1: natural history and effect of splenectomy and/or enzyme replacement therapy. Isr Med Assoc J 2000; 2:158.
  56. Pastores GM, Wallenstein S, Desnick RJ, Luckey MM. Bone density in Type 1 Gaucher disease. J Bone Miner Res 1996; 11:1801.
  57. Lachmann RH, Grant IR, Halsall D, Cox TM. Twin pairs showing discordance of phenotype in adult Gaucher's disease. QJM 2004; 97:199.
  58. Maaswinkel-Mooij P, Hollak C, van Eysden-Plaisier M, et al. The natural course of Gaucher disease in The Netherlands: implications for monitoring of disease manifestations. J Inherit Metab Dis 2000; 23:77.
  59. Piran S, Roberts A, Patterson MA, Amato D. The clinical course of untreated Gaucher disease in 22 patients over 10 years: hematological and skeletal manifestations. Blood Cells Mol Dis 2009; 43:289.
  60. Boomsma JM, van Dussen L, Wiersma MG, et al. Spontaneous regression of disease manifestations can occur in type 1 Gaucher disease; results of a retrospective cohort study. Blood Cells Mol Dis 2010; 44:181.
  61. Weinreb NJ, Deegan P, Kacena KA, et al. Life expectancy in Gaucher disease type 1. Am J Hematol 2008; 83:896.
  62. Lee RE. The pathology of Gaucher disease. In: Gaucher disease: A century of delineation and research, Desnick RJ, Gatt S, Grabowski GA (Eds), Alan R. Liss, New York 1982. p.177.
  63. Shiran A, Brenner B, Laor A, Tatarsky I. Increased risk of cancer in patients with Gaucher disease. Cancer 1993; 72:219.
  64. Arends M, van Dussen L, Biegstraaten M, Hollak CE. Malignancies and monoclonal gammopathy in Gaucher disease; a systematic review of the literature. Br J Haematol 2013; 161:832.
  65. Mignot C, Doummar D, Maire I, et al. Type 2 Gaucher disease: 15 new cases and review of the literature. Brain Dev 2006; 28:39.
  66. Zimran A, Morris E, Mengel E, et al. The female Gaucher patient: the impact of enzyme replacement therapy around key reproductive events (menstruation, pregnancy and menopause). Blood Cells Mol Dis 2009; 43:264.
  67. Granovsky-Grisaru S, Belmatoug N, vom Dahl S, et al. The management of pregnancy in Gaucher disease. Eur J Obstet Gynecol Reprod Biol 2011; 156:3.
  68. Elstein Y, Eisenberg V, Granovsky-Grisaru S, et al. Pregnancies in Gaucher disease: a 5-year study. Am J Obstet Gynecol 2004; 190:435.